Publisher's Synopsis
Drugs in Context is an independent, peer reviewed and practice orientated review of all the significant data on a specific drug, placed in the context of the disease and clinical practice setting. Niaspan(R); Editorial: "If we just focus on dyslipidaemia, it is evident that a less aggressive approach will have less benefit and a more vigorous approach has more benefit. Looking into the future, if we adopt the aggressive philosophy, cardiovascular disease could be reduced by 50 per cent or more." Disease Overview: "In 1994, the landmark Scandinavian Simvastatin Survival Study showed that in patients with established coronary heart disease (CHD) and hypercholesterolaemia, effective lipid lowering led to a 30 per cent reduction in mortality and significant reductions in coronary events." Drug Review: "Niaspan(R) is an extended-release formulation of nicotinic acid, or niacin, developed in order to provide the same lipid-lowering effects of the original nicotinic acid, but with an improved tolerability and safety profile." Improving Practice: "The burden of cardiovascular disease in the UK is large and is likely to increase as the population ages.;At current rates, nearly half the population will die from a cardiovascular cause and so the problem impacts on all healthcare professionals."
